211 related articles for article (PubMed ID: 23898112)
41. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.
Lee KS; Chung HC; Im SA; Park YH; Kim CS; Kim SB; Rha SY; Lee MY; Ro J
Breast Cancer Res Treat; 2008 Mar; 108(2):241-50. PubMed ID: 17476588
[TBL] [Abstract][Full Text] [Related]
42. Phase II multi-institutional prospective trial of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer refractory to fluoropyrimidine with modified dose reduction criteria (CCOG1303).
Kobayashi D; Mochizuki Y; Torii K; Takeda S; Kawase Y; Ishigure K; Teramoto H; Ando M; Kodera Y
Int J Clin Oncol; 2020 Oct; 25(10):1793-1799. PubMed ID: 32567012
[TBL] [Abstract][Full Text] [Related]
43. Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.
Moon YW; Sohn JH; Choi HJ; Chang H; Park BW; Kim SI; Park S; Koo JS; Kim YT; Roh JK; Chung HC; Kim JH
Cancer Chemother Pharmacol; 2010 Aug; 66(3):425-31. PubMed ID: 20012956
[TBL] [Abstract][Full Text] [Related]
44. Weekly paclitaxel--an effective treatment for advanced breast cancer.
Kellokumpu-Lehtinen P; Tuunanen T; Asola R; Elomaa L; Heikkinen M; Kokko R; Järvenpää R; Lehtinen I; Maiche A; Kaleva-Kerola J; Huusko M; Möykkynen K; Ala-Luhtala T
Anticancer Res; 2013 Jun; 33(6):2623-7. PubMed ID: 23749918
[TBL] [Abstract][Full Text] [Related]
45. Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis.
Zong Y; Wu J; Shen K
Oncotarget; 2017 Mar; 8(10):17360-17372. PubMed ID: 28061451
[TBL] [Abstract][Full Text] [Related]
46. Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.
Nisticò C; Bria E; Cuppone F; Fornier M; Sperduti I; Carpino A; Pace A; Cognetti F; Terzoli E
Anticancer Drugs; 2007 Jul; 18(6):687-92. PubMed ID: 17762397
[TBL] [Abstract][Full Text] [Related]
47. Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab.
Polyzos A; Kalbakis K; Kentepozidis N; Giassas S; Kalykaki A; Vardakis N; Bozionelou V; Saloustros E; Kontopodis E; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2011 Jul; 68(1):217-23. PubMed ID: 20922389
[TBL] [Abstract][Full Text] [Related]
48. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
[TBL] [Abstract][Full Text] [Related]
49. Weekly paclitaxel in women with heavily pretreated metastatic breast cancer: a retrospective analysis of cases treated at the Chang Gung Memorial Hospital.
Lu CH; Lin YC; Chang HK
Chang Gung Med J; 2007; 30(1):33-40. PubMed ID: 17477027
[TBL] [Abstract][Full Text] [Related]
50. Apparent beneficial effects by nab-paclitaxel in the treatment of refractory metastatic ovarian carcinoma.
Agheli A; Park SC; Huang CJ; Wang JC
Anticancer Drugs; 2009 Jul; 20(6):525-6. PubMed ID: 19568002
[No Abstract] [Full Text] [Related]
51. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
Gradishar WJ; Tjulandin S; Davidson N; Shaw H; Desai N; Bhar P; Hawkins M; O'Shaughnessy J
J Clin Oncol; 2005 Nov; 23(31):7794-803. PubMed ID: 16172456
[TBL] [Abstract][Full Text] [Related]
52. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
Socinski MA; Bondarenko I; Karaseva NA; Makhson AM; Vynnychenko I; Okamoto I; Hon JK; Hirsh V; Bhar P; Zhang H; Iglesias JL; Renschler MF
J Clin Oncol; 2012 Jun; 30(17):2055-62. PubMed ID: 22547591
[TBL] [Abstract][Full Text] [Related]
53. EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer.
Biganzoli L; Cinieri S; Berardi R; Pedersini R; McCartney A; Minisini AM; Caremoli ER; Spazzapan S; Magnolfi E; Brunello A; Risi E; Palumbo R; Leo S; Colleoni M; Donati S; De Placido S; Orlando L; Pistelli M; Parolin V; Mislang A; Becheri D; Puglisi F; Sanna G; Zafarana E; Boni L; Mottino G
Breast Cancer Res; 2020 Aug; 22(1):83. PubMed ID: 32758299
[TBL] [Abstract][Full Text] [Related]
54. [Administration of low-dose albumin-bound paclitaxel for the treatment of advanced and recurrent breast cancer patients].
Kawamura M; Nakano S; Kyoda S; Tabei I; Yoshida K; Takeyama H
Gan To Kagaku Ryoho; 2013 Jul; 40(7):909-12. PubMed ID: 23863734
[TBL] [Abstract][Full Text] [Related]
55. [Nanoparticle albumin-bound Paclitaxel for unresectable or recurrent gastric cancer].
Egawa T; Kemmochi T; Nishiya S; Mihara K; Ito Y; Nagashima A
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2251-3. PubMed ID: 25731486
[TBL] [Abstract][Full Text] [Related]
56. [Complete response of advanced breast cancer with lymph node metastases to nab-paclitaxel therapy-report of a case].
Hara Y; Sakurai K; Enomoto K; Matsumoto K; Ueda Y; Hagiwara M; Waga E; Nagashima S; Tani M; Amano S
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2080-2. PubMed ID: 23267983
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial.
Ducreux M; Bennouna J; Adenis A; Conroy T; Lièvre A; Portales F; Jeanes J; Li L; Romano A
Cancer Chemother Pharmacol; 2017 Jan; 79(1):9-16. PubMed ID: 27866244
[TBL] [Abstract][Full Text] [Related]
58. [Nab-paclitaxel].
Lopez-Trabada Ataz D; Dumont S; André T
Bull Cancer; 2015 Jun; 102(6):568-76. PubMed ID: 26008630
[TBL] [Abstract][Full Text] [Related]
59. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
[TBL] [Abstract][Full Text] [Related]
60. A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer.
Ciruelos E; Apellániz-Ruiz M; Cantos B; Martinez-Jáñez N; Bueno-Muiño C; Echarri MJ; Enrech S; Guerra JA; Manso L; Pascual T; Dominguez C; Gonzalo JF; Sanz JL; Rodriguez-Antona C; Sepúlveda JM
Oncologist; 2019 Nov; 24(11):e1024-e1033. PubMed ID: 31023863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
